Company Background
Verisense Health was launched in January 2023 as a spin-off from the Dublin, Ireland based wearable technology services and sensor manufacturer Shimmer Research. Most Shimmer Research staff members in Boston, Malaysia and Dublin who focus on clinical research have now joined Verisense Health. Shimmer Research also provided initial funding, marketing, administration, and quality control support for Verisense Health. Such operations are now operating completely independently. Former president of Shimmer Americas, Geoff Gill, lead the spin-out as CEO of Verisense Health.
Verisense Health has become the sole marketer of the modular Verisense wearable sensor platform, which Shimmer Research developed from the ground up for use in clinical trials and remote patient research. The Verisense platform is open to non-Shimmer Research hardware. Verisense Health also assumed ownership of the Verisense Digital Health Panel (DHP), which was launched in 2022 to provide clinical researchers with access to raw, real-world, digital health ground-truth sensor data.
Headquartered out of Cambridge, Massachusetts, USA, Verisense Health is digital health software and data management company. It was established with the goal of providing sponsors with cost-efficient access to a digital biobank of longitudinal raw patient data.
Mission - To accelerate the adoption of and maximize the benefit of digital health technology through pre-competitive collaboration.
Vision - To build a Digital Biobank of digital health data connected to real world outcomes to accelerate the development and validation of digital health technologies by enabling sharing and reuse of data and promoting collaboration.
Values:
Collaboration - we will work collaboratively, both internally and externally to realize our vision and mission. Differing opinions are encouraged and valued, but we work together once a direction is chosen.
Equity - we will treat everyone equitably and will not tolerate prejudice of any kind.
Decisiveness - speed is of the essence, and we will make decisions quickly, sometimes with incomplete information. We will not allow decisions to be made because of inaction.
Transparency - we will be as open as possible, both internally and externally.
Why Spin-Off Verisense Health?
Several factors prompted the launch of Verisense Health. Shimmer Research is involved in many markets but as a standalone firm Verisense Health can devote all its attention to digital health, become technology agnostic, and scale much faster by focusing solely on data collection and software development. Our customer support will also be more finely focused. Shimmer Research will continue to supply Verisense Health with wearable sensors on an ongoing basis. However, Verisense Health will also purchase sensors and other digital health technologies from third-party providers.
We are working toward a world in which wearable sensors and other digital health technologies can tell people they are getting sick before they know it, and doctors can transition from reactively treating illnesses to proactively managing them. For that to occur, we need to capture reliable, minimally processed ‘raw,’ real-world data that can serve as a ground truth for any analysis validating new algorithms and comparing them head-to-head with current state of the art algorithms. Verisense Health will achieve that goal through The Verisense Digital Health Panel.
Currently, most wearable devices use proprietary algorithms and processed data to measure steps and sleep patterns, which often give different results. For example, the Digital Medical Society’s (DiMe’s) Library of Digital Endpoints already contains 70 activity measures and 55 sleep measures.
Healthcare stakeholders need to work together to create a transparent, ground truth dataset using raw data and open algorithms. This will enable the development of standardized digital biomarkers and endpoints in which regulators, payors, and patients can have more confidence and trust.
Our Verisense Digital Health Panel infrastructure makes us an extremely cost-efficient collector of digital health data for existing clinical trials, turnkey studies, and companion studies. By aggregating all that raw data in one place, we are building a digital biobank that will enable researchers to conduct future scientific studies without needing to collect new data. Our customers will benefit from gaining access to a low-cost, low-burden digital health data collection service, best-in-class digital health technologies, and a growing database of raw digital health data with associated outcomes – both patient reported and real-world data. Customers will pay only for the data delivered and not for the hardware, software, and specific services.
